151 related articles for article (PubMed ID: 9822145)
1. Calcium antagonists and cardiovascular risk in diabetes.
Parving HH
Am J Cardiol; 1998 Nov; 82(9B):42R-44R. PubMed ID: 9822145
[TBL] [Abstract][Full Text] [Related]
2. Calcium antagonists and the diabetic patient: a response to recent controversies.
Poulter NR
Am J Cardiol; 1998 Nov; 82(9B):40R-41R. PubMed ID: 9822144
[TBL] [Abstract][Full Text] [Related]
3. CCBs vs ACE inhibitors in patients with diabetes.
Zamorski MA
J Fam Pract; 1998 Jul; 47(1):12-3. PubMed ID: 9673598
[No Abstract] [Full Text] [Related]
4. Comorbidity of hypertension and diabetes: the fosinopril versus amlodipine cardiovascular events trial (FACET).
Sowers JR
Am J Cardiol; 1998 Nov; 82(9B):15R-19R. PubMed ID: 9822138
[TBL] [Abstract][Full Text] [Related]
5. New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes.
Pahor M; Psaty BM; Furberg CD
J Cardiovasc Pharmacol; 1998; 32 Suppl 2():S18-23. PubMed ID: 9736437
[TBL] [Abstract][Full Text] [Related]
6. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
Dahlöf B; Sever PS; Poulter NR; Wedel H; Beevers DG; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Lancet; 2005 Sep 10-16; 366(9489):895-906. PubMed ID: 16154016
[TBL] [Abstract][Full Text] [Related]
7. Combinations of inhibitors of the renin-angiotensin system with calcium channel blockers for the treatment of hypertension: focus on perindopril/amlodipine.
Mourad JJ; Le Jeune S; Pirollo A; Mourad C; Gaudouen Y; Lopez-Sublet M
Curr Med Res Opin; 2010 Sep; 26(9):2263-76. PubMed ID: 20690889
[TBL] [Abstract][Full Text] [Related]
8. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.
Tatti P; Pahor M; Byington RP; Di Mauro P; Guarisco R; Strollo G; Strollo F
Diabetes Care; 1998 Apr; 21(4):597-603. PubMed ID: 9571349
[TBL] [Abstract][Full Text] [Related]
9. Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials.
Lv Y; Zou Z; Chen GM; Jia HX; Zhong J; Fang WW
Blood Press Monit; 2010 Aug; 15(4):195-204. PubMed ID: 20512032
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes.
Pahor M; Psaty BM; Alderman MH; Applegate WB; Williamson JD; Furberg CD
Diabetes Care; 2000 Jul; 23(7):888-92. PubMed ID: 10895836
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hypertensive patients with diabetes.
Pahor M; Psaty BM; Furberg CD
Lancet; 1998 Mar; 351(9104):689-90. PubMed ID: 9504510
[No Abstract] [Full Text] [Related]
12. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Bakris GL; Sarafidis PA; Weir MR; Dahlöf B; Pitt B; Jamerson K; Velazquez EJ; Staikos-Byrne L; Kelly RY; Shi V; Chiang YT; Weber MA;
Lancet; 2010 Apr; 375(9721):1173-81. PubMed ID: 20170948
[TBL] [Abstract][Full Text] [Related]
13. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
14. The Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) and combination therapies.
Pahor M; Tatti P
Am J Cardiol; 1999 Mar; 83(5):819-20. PubMed ID: 10080455
[No Abstract] [Full Text] [Related]
15. [Hypertension therapy in practice test. Calcium antagonist receives good marks].
Keck M; Sauerbrey-Wullkopf N; Regourd E; Clemens A
MMW Fortschr Med; 2005 Jan; 147(1-2):51. PubMed ID: 15704573
[No Abstract] [Full Text] [Related]
16. Current recommendations for the treatment of hypertension: are they still valid?
Moser M
J Hypertens Suppl; 2002 Feb; 20(1):S3-10. PubMed ID: 11996197
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive treatment and CHD in the elderly.
Fink KS; Ellsworth A
Am Fam Physician; 1999 Sep; 60(4):1102, 1104, 1107. PubMed ID: 10507742
[No Abstract] [Full Text] [Related]
18. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Jamerson K; Weber MA; Bakris GL; Dahlöf B; Pitt B; Shi V; Hester A; Gupte J; Gatlin M; Velazquez EJ;
N Engl J Med; 2008 Dec; 359(23):2417-28. PubMed ID: 19052124
[TBL] [Abstract][Full Text] [Related]
19. Hypertension and diabetes and the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). More ammunition against surrogate end points.
Califf RM; Granger CB
Diabetes Care; 1998 Apr; 21(4):655-7. PubMed ID: 9571359
[No Abstract] [Full Text] [Related]
20. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
Scheen AJ
Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
